Drugs / BIIB022
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00970580 | Oct 2009 → Sep 2011 | non-small cell lung carcinoma | Biogen | Completed | No outcome recorded |
| Phase 1 | NCT00956436 | Aug 2009 → Apr 2011 | hepatocellular carcinoma | Biogen | Completed | No outcome recorded |
| Phase 1 | NCT00555724 | Jan 2008 → Apr 2010 | cancer | Biogen | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BIIB022 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00956436 ↗ |
| Modality | Monoclonal antibody | “Anti-IGF-1R Monoclonal Antibody” NCT00555724 ↗ |
| Route | Intravenous | “IV infusion once every three weeks until disease progression or unacceptable toxicity” NCT00555724 ↗ |
| Target | IGF1R | “Anti-IGF-1R Monoclonal Antibody” NCT00555724 ↗ |